{"slug":"tesamorelin-glp1-gut","verification":{"valid":true,"entries":2,"head":"3a9ada3606f124d854b28242cee7e9e63ced907a99396881dcb01ae8428f56e6"},"energy":{"passes":2,"tokens_in":16860,"tokens_out":3076,"tokens_total":19936,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"3a9ada3606f124d854b28242cee7e9e63ced907a99396881dcb01ae8428f56e6"},"provenance":[{"ts":"2026-06-29T23:21:46.646Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Glp1 Gut\nSlug: tesamorelin-glp1-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"GLP-1 gut damage / gastroparesis\",\"condition_key\":\"glp1-gut-damage\",\"primary_peptide\":\"tesamorelin\",\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[\"glp1-agonists\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have GLP-1 gut damage / gastroparesis\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\",\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\\n2. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[{\"drug\":\"glp1-agonists\",\"name\":\"GLP-1 agonists (class)\",\"section_title\":\"Why GLP-1 agonists (class) matters for you\",\"steps\":[\"**Drug:** GLP-1 agonists (class)\",\"**What it does:** Metabolic benefit vs gut slowing / muscle loss tradeoffs a","response":"{\n  \"slug\": \"tesamorelin-glp1-gut\",\n  \"title\": \"Tesamorelin for GLP-1 Gut Damage: GH Axis Evidence and Visceral Fat Context\",\n  \"body\": \"## What's breaking down if you have GLP-1 gut damage / gastroparesis\\n\\nGLP-1 agonists slow gastric emptying as part of their mechanism. This can lead to symptoms like nausea, bloating, early satiety, and in some cases diagnosed gastroparesis. The effect is often dose-dependent and reversible upon stopping the drug in reported cases.\\n\\nDegeneration here centers on motility disruption rather than permanent structural loss in most descriptions. Repair pathways would focus on restoring normal gastric motility and enteric nerve signaling. Suppression of symptoms or metabolic benefits from the drug itself trades off against this motility slowdown.\\n\\nNo direct condition profile matched the exact slug, so layers are inferred from drug class effects and GH-related studies: gut motility slowdown versus potential upstream hormonal influences on tissue repair via growth hormone pathways.\\n\\n## Why Tesamorelin might help you\\n\\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\\n2. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\\n\\nTesamorelin stimulates endogenous growth hormone release through the GHRH axis. This raises IGF-1 levels and promotes lipolysis focused on visceral adipose tissue. In the context of GLP-1 use, visceral fat reduction occurs without direct impact on gastric emptying speed.\\n\\nIf visceral fat accumulation adds mechanical or inflammatory load around abdominal organs, lowering it could indirectly support gut environment. The logic chain runs: elevated GH signaling → targeted visceral fat loss → potential improvement in abdominal tissue dynamics. This differs from GLP-1 action, which slows emptying for satiety but can exacerbate motility complaints.\\n\\nHuman data ","tokens_in":16860,"tokens_out":3076,"cost":0,"prev":"genesis","hash":"f4a0a1861386250c2f706f033ddcf466cc72e02349e2b2bd9c2b8cc13e5fdea0"},{"ts":"2026-07-17T02:42:22.888Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-glp1-gut","response":"32 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f4a0a1861386250c2f706f033ddcf466cc72e02349e2b2bd9c2b8cc13e5fdea0","hash":"3a9ada3606f124d854b28242cee7e9e63ced907a99396881dcb01ae8428f56e6"}]}